(SLNO) – Company Press Releases
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
-
Soleno Therapeutics to Present at Upcoming February Investor Conferences
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
-
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
-
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
-
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Opti
-
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
-
Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
-
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
-
Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
-
Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
-
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
-
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
-
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
-
Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
-
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
-
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
-
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
-
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
-
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
-
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
-
Soleno Therapeutics Announces Presentations at ENDO 2022
-
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
-
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
-
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
-
Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
-
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
-
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
-
Soleno Therapeutics Announces Proposed Underwritten Public Offering
-
Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome
-
Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
-
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
-
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Back to SLNO Stock Lookup
